MX2020000673A - Composiciones que contienen conjugados análogos de cannabinoides y métodos de uso. - Google Patents

Composiciones que contienen conjugados análogos de cannabinoides y métodos de uso.

Info

Publication number
MX2020000673A
MX2020000673A MX2020000673A MX2020000673A MX2020000673A MX 2020000673 A MX2020000673 A MX 2020000673A MX 2020000673 A MX2020000673 A MX 2020000673A MX 2020000673 A MX2020000673 A MX 2020000673A MX 2020000673 A MX2020000673 A MX 2020000673A
Authority
MX
Mexico
Prior art keywords
methods
compositions containing
compositions
cannabinoid analog
analog conjugates
Prior art date
Application number
MX2020000673A
Other languages
English (en)
Inventor
Jerry L Bryant Jr
David J Yang
Jana Rauvolfova
Tori Strong
Original Assignee
Vyripharm Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyripharm Entpr Llc filed Critical Vyripharm Entpr Llc
Publication of MX2020000673A publication Critical patent/MX2020000673A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presenta se proporcionan composiciones que contienen un conjugado de una etiqueta, un quelante y un análogo cannabinoide, así como métodos para diagnosticar, tratar o controlar la progresión de un cáncer o un trastorno neurológico utilizando estas composiciones. En la presente también se proporcionan métodos para sintetizar estas composiciones y kits para la administración de estas composiciones como agentes de imagenología y terapéuticos.
MX2020000673A 2017-07-18 2018-07-18 Composiciones que contienen conjugados análogos de cannabinoides y métodos de uso. MX2020000673A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533894P 2017-07-18 2017-07-18
PCT/US2018/042707 WO2019018536A1 (en) 2017-07-18 2018-07-18 COMPOSITIONS CONTAINING CONJUGATES OF CANNABINOID ANALOGUES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
MX2020000673A true MX2020000673A (es) 2020-07-29

Family

ID=65016693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000673A MX2020000673A (es) 2017-07-18 2018-07-18 Composiciones que contienen conjugados análogos de cannabinoides y métodos de uso.

Country Status (10)

Country Link
EP (1) EP3654971A4 (es)
JP (1) JP2020527589A (es)
KR (1) KR20200031663A (es)
CN (1) CN111065391A (es)
AU (1) AU2018302155B2 (es)
CA (1) CA3070538A1 (es)
EA (1) EA202090116A1 (es)
IL (1) IL272060A (es)
MX (1) MX2020000673A (es)
WO (1) WO2019018536A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3986388A4 (en) * 2019-06-24 2024-02-21 Diverse Biotech, Inc. CANNABINOID CONJUGATE MOLECULES
EP4045023A4 (en) * 2019-10-15 2023-09-13 Diverse Biotech, Inc. CONJUGATED MOLECULES
CN112807301A (zh) * 2020-12-30 2021-05-18 福建省中科生物股份有限公司 麻类植物提取化合物Cannabiorcol在制备抗肿瘤药物上的用途
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305148A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Natural cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
US20220305145A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Compositions and methods for diagnosing viral infections including covid-19 and for infection severity monitoring as well as targeted detection of cytokine storm

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530087A1 (en) * 2003-06-30 2005-02-03 Merck & Co., Inc. Radiolabeled cannabinoid-1 receptor modulators
JP2009534381A (ja) * 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
WO2009029727A1 (en) * 2007-08-28 2009-03-05 Vanderbilt University Cannabinoid receptor targeted agent
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
EP2992880A1 (en) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate

Also Published As

Publication number Publication date
JP2020527589A (ja) 2020-09-10
EA202090116A1 (ru) 2020-05-14
WO2019018536A1 (en) 2019-01-24
IL272060A (en) 2020-03-31
AU2018302155A1 (en) 2020-02-06
CN111065391A (zh) 2020-04-24
KR20200031663A (ko) 2020-03-24
CA3070538A1 (en) 2019-01-24
EP3654971A1 (en) 2020-05-27
EP3654971A4 (en) 2021-04-21
AU2018302155B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2020000673A (es) Composiciones que contienen conjugados análogos de cannabinoides y métodos de uso.
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
MX2018009496A (es) Degradadores selectivos del receptor de estrogeno y sus usos.
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
NZ769136A (en) Nlrp3 modulators
MX2018005061A (es) Compuestos de interacción con glicanos y métodos de uso.
NZ754865A (en) Combination therapy for the treatment of cancer
MX2020006010A (es) Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
TN2019000211A1 (en) Antitumoral compounds
SG10201803112RA (en) Liquid treatment apparatus
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MY200161A (en) Bacteria for targeting tumors and treating cancer
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
PH12019502694A1 (en) Anti-trkb antibodies
AU2018301651A1 (en) A peptide saporin conjugate for the treatment of cancer
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors